LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

Source: 
CP Wire
snippet: 
  • LEO Pharma is committed to$70 million comprised of equity financing and financial R&D support
  • PellePharm and its stockholders could receive up to an additional $690 million including merger consideration, and regulatory and commercial milestone payments